Memantine Hydrochloride Capsule, Extended Release
Product Images NDC 68382-548

9 FDA label images from Zydus Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 68382-548). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 01)

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 01)
Chemical structure of Memantine hydrochloride, showing the amine group (NH2) attached to a bicyclic ring system along with methyl groups and hydrochloride component (HCl).*
FDA Label Image

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 02)

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 02)
A line graph comparing the mean change from baseline in SIB score over 24 weeks of treatment between memantine hydrochloride extended-release capsule 28 mg and placebo. The x-axis represents weeks of treatment, and the y-axis shows mean change in SIB score, with clinical improvement above zero and clinical decline below. Memantine shows an increase peaking around week 12, then a slight decline but remains above baseline, whereas placebo shows an increase peaking near week 8 followed by a marked decline toward baseline by week 24.*
FDA Label Image

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 03)

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 03)
A cumulative percentage line graph showing patients on the vertical axis and SIB change from baseline on the horizontal axis. Two lines are compared: one representing Memantine hydrochloride extended-release capsule 28 mg and the other a placebo, both related to the parameter AChEI.*
FDA Label Image

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 04)

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 04)
A line graph depicting Mean (± SEM) CIBIC-Plus Scores over 24 weeks of treatment comparing Memantine hydrochloride extended-release capsule 28 mg with placebo. The y-axis represents the score, while the x-axis shows treatment duration in weeks. The graph includes labels for clinical improvement and clinical decline, illustrating treatment effects over time.*
FDA Label Image

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 05)

Memantine HCl Er Capsules (079cb172 4d62 4571 98b9 5ad01706dbee 05)
A bar chart comparing the percentage of patients on Memantine hydrochloride extended-release capsule 28 mg/AChEI versus placebo/AChEI across different categories of the CIBIC Plus Rating, including marked improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, and marked worsening.*
FDA Label Image

Memantine Hydrochloride Extended-release Capsules, 7 mg (079cb172 4d62 4571 98b9 5ad01706dbee 06)

Memantine Hydrochloride Extended-release Capsules, 7 mg (079cb172 4d62 4571 98b9 5ad01706dbee 06)
Memantine Hydrochloride Extended-Release Capsules 7 mg oral capsules, 30 count, by Zydus Pharmaceuticals USA Inc. The label states the product is for once-daily use and notes child-resistant packaging. Storage instructions indicate to keep at 20°C to 25°C (68°F to 77°F) and out of reach of children. The product is manufactured by Zydus Lifesciences Ltd., India, and distributed by Zydus Pharmaceuticals USA Inc.*
FDA Label Image

Memantine Hydrochloride Extended-release Capsules, 14 mg (079cb172 4d62 4571 98b9 5ad01706dbee 07)

Memantine Hydrochloride Extended-release Capsules, 14 mg (079cb172 4d62 4571 98b9 5ad01706dbee 07)
Memantine Hydrochloride Extended-release Capsules 14 mg by Zydus Pharmaceuticals USA Inc. The label displays the proprietary and generic name, strength (14 mg), dosage form (extended-release capsules), and package quantity (30 capsules). It includes storage instructions and manufacturer details for Zydus Lifesciences Ltd., India, distributed by Zydus Pharmaceuticals USA Inc.*
FDA Label Image

Memantine Hydrochloride Extended-release Capsules, 21 mg (079cb172 4d62 4571 98b9 5ad01706dbee 08)

Memantine Hydrochloride Extended-release Capsules, 21 mg (079cb172 4d62 4571 98b9 5ad01706dbee 08)
Label for Memantine Hydrochloride Extended-release Capsules 21 mg by Zydus Pharmaceuticals USA Inc. The label shows a package of 30 capsules, indicated for once-daily oral administration. It includes dosage strength prominently in a green box, manufacturer information, usage notes, and a barcode with NDC 68382-548-06.*
FDA Label Image

Memantine Hydrochloride Extended-release Capsules, 28 mg (079cb172 4d62 4571 98b9 5ad01706dbee 09)

Memantine Hydrochloride Extended-release Capsules, 28 mg (079cb172 4d62 4571 98b9 5ad01706dbee 09)
Memantine Hydrochloride Extended-release Capsules 28 mg oral dosage form by Zydus Pharmaceuticals USA Inc. The label indicates a 30-capsule package, child-resistant packaging, and storage instructions. The product is labeled for once-daily use and manufactured in Italy by Zydus Lifesciences Ltd., with distribution in the USA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.